RoosterBio
RoosterBio is a Frederick, Maryland-based biotechnology company that develops standardized human mesenchymal stem/stromal cells, exosome bioprocessing media, and cGMP clinical-grade materials sold to biotech companies, academic researchers, and clinical-stage advanced therapy developers across 25+ countries.
- Company typePrivate
- Founded2012
- HeadquartersFrederick, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What RoosterBio does
RoosterBio is a privately held biotechnology company founded in 2012 and headquartered in Frederick, Maryland, that develops and commercializes standardized human mesenchymal stem/stromal cell (hMSC) and exosome bioprocessing solutions for the regenerative medicine and advanced therapy industry. Its product portfolio spans human primary cells from bone marrow, adipose, umbilical cord, and neonatal dermal tissue; proprietary hMSC expansion media, bioreactor feeds, and exosome production media; cGMP CliniControl clinical-grade cells, media, and genetic engineering materials supported by Type II FDA Master Files; hTERT-modified engineered cell lines; genetic engineering tools (GEM); MSC-derived exosomes with downstream processing solutions; and bundled starter, screening, and bioreactor kits. The company also offers process development, hMSC analytical, and exosome/EV analytical services.
RoosterBio sells primarily through a direct e-commerce channel supported by a sales-led B2B go-to-market targeting biotech and pharma companies, academic and research institutions, and clinical/translational research organizations across 25+ countries and 6 continents, with an exclusive distribution partnership with MineBio Life Sciences covering China. Revenue is generated mainly through one-time product sales of cells, media, kits, and cGMP materials, supplemented by professional services revenue. The company has raised approximately $41M cumulatively across disclosed rounds and SEC Form D exempt offerings, with the most recent ~$12M 2024 offering combining equity and debt securities. Scientific validation is anchored by 350+ peer-reviewed citations of RoosterBio products since 2015, and the platform is designed to lower the cost and complexity of incorporating hMSCs into therapeutic development programs from research through clinical manufacturing.
RoosterBio firmographics
Firmographics- Name
- RoosterBio
- Legal name
- RoosterBio, Inc.
- Website
- https://roosterbio.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- RoosterBio is a Frederick, Maryland-based biotechnology company that develops standardized human mesenchymal stem/stromal cells, exosome bioprocessing media, and cGMP clinical-grade materials sold to biotech companies, academic researchers, and clinical-stage advanced therapy developers across 25+ countries.
- Ownership category
- akta.pro rank
RoosterBio industry classification
Industry- Product category
- Cell Therapy and Regenerative Medicine Raw Materials
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)
- akta.pro secondary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where RoosterBio is headquartered
LocationHeadquarters
- HQ city
- Frederick
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RoosterBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Human Primary Cells Sales: Sale of human mesenchymal stem/stromal cells from multiple tissue sources (bone marrow, adipose, umbilical cord) and engineered cell lines. Products available as research-grade and cGMP clinical-grade for therapeutic development.
- Cell & Exosome Media: Sale of specialized cell culture media, supplements, and bioreactor feed products for MSC expansion and exosome production. Includes QuickShip options for rapid fulfillment.
- Process Development & Analytical Services: Contract services including process development support, hMSC analytical services, and exosome/EV analytical services to help customers optimize their manufacturing workflows.
- cGMP CliniControl Products: Clinical-grade raw materials and starting materials for advanced therapy manufacturing, supported by regulatory documentation including Type II FDA Master Files.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels9 records
RoosterBio product offering
Product offeringCore offering
RoosterBio manufactures and sells standardized, off-the-shelf human mesenchymal stem/stromal cells (hMSCs), exosomes, and cGMP-grade cell and exosome bioprocessing media used by cell therapy developers and translational researchers. The company also offers process development and analytical services that support scale-up from research to clinical manufacturing.
Product overview
RoosterBio offers an integrated portfolio of products and services for mesenchymal stem/stromal cell (hMSC) and exosome-based therapeutic development. The portfolio comprises three core product lines: (1) Human Primary Cells including bone marrow-, adipose-, and umbilical cord-derived hMSCs plus neonatal dermal fibroblasts, available in standard and QuickShip™ formats; (2) Cell & Exosome Media including hMSC expansion media, bioreactor feeds, and exosome production media, available in both research-grade and cGMP CliniControl™ formats; and (3) Human Exosomes/Extracellular Vesicles including MSC-derived exosomes with QuickShip™ and downstream processing options. Supporting products include hTERT-modified engineered cell lines, genetic engineering tools, and bundled starter/screening/bioreactor kits. Services encompass process development, analytical testing for hMSCs and exosomes, and QuickShip™ solutions. The platform is designed to accelerate translation from research through clinical manufacturing, with cGMP CliniControl™ products supported by Type II FDA Master Files.
Differentiator
Problem solved
Functional benefit
Brands
- CliniControl: cGMP CliniControl products for clinical-grade cell therapy manufacturing
- QuickShip
- RoosterVial
- RoosterKit
- GEM
Products and services
- Human Primary Cells Off-the-shelf human mesenchymal stem/stromal cells derived from bone marrow, adipose, and umbilical cord tissue, supplied to research and translational customers for use in basic and pre-clinical studies.
- Cell & Exosome Media Defined, xeno-free bioprocessing media designed for hMSC expansion and exosome production, intended for cell therapy developers and translational researchers.
- cGMP CliniControl Products Clinical-grade, cGMP-manufactured hMSCs and media, supported by FDA Master Files, for use in cell therapy manufacturing intended for clinical and commercial applications.
- Engineered Cell Lines Genetically engineered human mesenchymal stem cell lines offered as research tools for disease modeling and targeted cell therapy applications.
- Genetic Engineering Tools Reagents and tools used to genetically modify hMSCs, supporting customers developing engineered cell therapy products.
- Kits Application-specific bundled kits combining primary cells, media, and protocols for targeted research workflows.
- Exosomes hMSC-derived exosomes supplied as standalone products for research, pre-clinical studies, and potential therapeutic development.
- Process Development Services Custom bioprocess development and scale-up services helping customers translate lab-scale hMSC and exosome protocols into manufacturing-ready processes.
- Analytical Services Analytical and characterization services for cells and exosomes, supporting release testing and quality control for cell therapy and exosome programs.
Quantifiable outcome
- Over 350 peer-reviewed publications cite RoosterBio cells and media
- +2 more outcomes
Companies that use RoosterBio
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
RoosterBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
RoosterBio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MineBio Life SciencescoreExclusive distribution partnership where MineBio Life Sciences will supply RoosterBio's MSC and exosome bioprocessing media in China. MineBio has secured import approval for these products, enabling immediate order fulfillment. This partnership supports research-grade and cGMP manufacturing solutions for developers across China, addressing the country's growing regenerative medicine sector.
Scale indicators6 records
Recent moves6 records
Expansion highlights3 records
RoosterBio competitors and assessment
Company assessmentBroad incumbents
- Lonza: Global CDMO leader offering cell and gene therapy manufacturing services and cGMP-grade raw materials. Overlaps with RoosterBio's CliniControl franchise and broader cell therapy manufacturing services but operates at much greater scale across multiple modalities.
- Thermo Fisher Scientific: Diversified life science tools and bioproduction leader with Gibco cell culture media and bioprocessing consumables directly competing with RoosterBio's expansion media and bioreactor feed product lines across research and cGMP applications.
- Cytiva: Danaher-owned bioprocessing platform offering bioreactors, cell culture media, and process development services. Overlaps with RoosterBio's 3D bioreactor kits, expansion media, and process development services for cell therapy manufacturing.
- Bio-Techne: Developer and manufacturer of purified proteins (R&D Systems) and GMP-grade cytokines used in cell therapy manufacturing. Overlaps with RoosterBio's media and ancillary raw materials offerings for clinical-stage cell therapy developers.
- Corning Life Sciences: Major manufacturer of cell culture vessels, surfaces, and media supplements used in MSC bioprocessing. Overlaps with RoosterBio's bioreactor and expansion media workflows through complementary consumables rather than direct product competition.
Direct peers
- CellGenix: German-headquartered supplier of GMP-grade raw materials and cytokines for cell and gene therapy manufacturing. Closest direct competitor to RoosterBio's CliniControl cGMP products, serving overlapping clinical and commercial manufacturing customers.
- Miltenyi Biotec: Provider of cell and gene therapy manufacturing solutions including MACS GMP products, bioreactors, and process development services. Competes directly with RoosterBio's cGMP raw materials and bioprocessing platform for cell therapy developers.
- STEMCELL Technologies: Supplier of cell culture media, primary cells, and tools for stem cell research and regenerative medicine. Directly comparable to RoosterBio's research-grade MSC products, expansion media, and differentiation tools across academic and industrial customers.
- PromoCell: German supplier of primary human cells including hMSCs, along with defined cell culture media. Directly comparable niche competitor to RoosterBio's primary cells portfolio serving academic and biotech customers.
Emerging players
- ZenBio: Supplier of primary cells, MSC products, and 3D tissue models for research applications. Smaller-scale emerging peer with overlapping MSC and adipose-derived cell products competing in research-grade market segments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
RoosterBio social profiles
Digital presenceRoosterBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
RoosterBio leadership team
Management profileNumber of profiles
Profiles1 record
RoosterBio funding detail
Funding detailFunding overview
Funding rounds10 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RoosterBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RoosterBio
What does RoosterBio do?
RoosterBio manufactures and sells standardized, off-the-shelf human mesenchymal stem/stromal cells (hMSCs), exosomes, and cGMP-grade cell and exosome bioprocessing media used by cell therapy developers and translational researchers. The company also offers process development and analytical services that support scale-up from research to clinical manufacturing.
Is RoosterBio a public or private company?
RoosterBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was RoosterBio founded?
RoosterBio was founded in 2012. It employs 51 to 100 people.
Where is RoosterBio based?
RoosterBio is headquartered in Frederick, United States, in the North America region.
How does RoosterBio make money?
Four revenue lines are on record. Human Primary Cells Sales are the primary driver. The others are cell & Exosome Media, process Development & Analytical Services and cGMP CliniControl Products.
Who are RoosterBio's main competitors?
Broad incumbents on record are Lonza, Thermo Fisher Scientific, Cytiva, Bio-Techne and Corning Life Sciences. Direct peers are CellGenix, Miltenyi Biotec, STEMCELL Technologies and PromoCell. ZenBio is listed as an emerging player.
Does RoosterBio have an API?
No public API is recorded for RoosterBio.
What industry is RoosterBio in?
RoosterBio's product category is Cell Therapy and Regenerative Medicine Raw Materials. Its primary akta.pro industry code is HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.